|Day Low/High||3.10 / 3.14|
|52 Wk Low/High||2.55 / 5.39|
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Nov. 19, 2010.
Company Continues Its Plans to Rapidly Move Into a Phase 3 Program in 2011
Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Nov. 12, 2010.
Collaboration Expected to Generate High-Paying Jobs in Michigan
Company Preparing for Phase 3 Critical Limb Ischemia Clinical Program, Announcement of Final Phase 2 CLI 6-Month Results and Final IMPACT-DCM 6-Month Results
Independent Data Safety Monitoring Board Approves Protocol Amendment for Initiation of Extension Study Involving Control Patients and Encourages Company to Begin Patient Enrollment
Additional Results Showing Statistically Significant Improvement in Amputation-Free Survival to be Presented by Principal Investigator Richard Powell, M.D.; Webcast and Conference Call Scheduled for 3:30pm EDT
Ronnda L. Bartel, Ph.D., Named Chief Scientific Officer; Sharon Watling, Pharm.D., Appointed Vice President of Clinical and Regulatory Affairs
Principal Investigator Dr. Richard Powell to Present Interim Results From U.S. Phase 2b RESTORE-CLI Trial at the 2010 Vascular Annual Meeting(R) on June 11 in Boston, MA
Several stocks trading near $5 were moving on above-average volume during Friday's session.
Several stocks trading near $5 were moving on above-average volume during Wednesday's session.
Aastrom Biosciences receives delisting letter from Nasdaq for not remaining in compliance
Aastrom Biosciences jumps after FDA ends suspension of stem cells to treat heart disease
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.